In this article, we will discuss: 10 Best Brain-Computer Interface Stocks to Buy.
On May 10, Bloomberg reported that brain-computer interfaces are transitioning from experimental to early implementation, allowing users to control computers, robotic arms, and communication tools with neural signals. Researchers have developed implanted and non-invasive devices that translate brain activity into commands, helping patients with paralysis and neurological disorders to regain function. Based on the report, just a few hundred people have received implants due to limited regulatory permissions, but developments in artificial intelligence and hardware are speeding up progress and moving the industry toward an inflection point.
According to Bloomberg, investment momentum is rising in the area, with Elon Musk and Sam Altman backing it. Elon Musk’s Neuralink has implanted devices in over 20 patients and plans to scale to 20,000 per year by 2031, whereas Synchron has tested devices in approximately 10 patients. Bloomberg data showed US BCI funding touched $2.75 billion, while China’s sector surpassed 1.8 billion yuan in 2025, showing rising global investment and competition.
With that said, here are the 10 Best Brain-Computer Interface Stocks to Buy.
Methodology:
We used screeners to identify Best Brain-Computer Interface Stocks and limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds. We then identified those with the highest number of hedge fund holders, which we assessed using Insider Monkey’s database of hedge funds as of Q1 2026. The stocks are ranked in ascending order of the number of hedge fund holders.
Note: This list includes both pure-play BCI developers and supporting infrastructure businesses.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
10. CeriBell, Inc. (NASDAQ:CBLL)
Number of Hedge Fund Holders: 15
CeriBell, Inc. (NASDAQ:CBLL) is among the Best Brain-Computer Interface Stocks.
On June 8, CeriBell, Inc. (NASDAQ:CBLL) reported a study published in Critical Care Medicine that higher AI-detected seizure burden is linked with increased odds of disability results at discharge. It analyzed 359 adult patients across three academic centers.
The company said patients with a peak seizure burden of at least 90% were 3.4 times more likely to experience death or severe disability compared to those with no seizure burden. Hence, the elevated burden directly leads to poorer functional outcomes.
The medtech firm revealed that risk develops with time. It stated that each additional hour of AI-detected seizure activity nearly doubled the odds of severe disability or death, noting an adjusted odds ratio of 1.98.
Lead author Josef Parvizi said the algorithm detects clinically relevant biomarkers with prognosis, underlining potential for earlier intervention.
CEO Jane Chao said continuous monitoring allows live assessment and more informed clinical decisions.
CeriBell, Inc. (NASDAQ:CBLL) is a commercial-stage medical technology firm that works to transform the diagnosis and treatment of patients with severe neurological conditions.
9. NeuroPace, Inc. (NASDAQ:NPCE)
Number of Hedge Fund Holders: 23
On May 29, NeuroPace, Inc. (NASDAQ:NPCE) said it received U.S. Food and Drug Administration approval for ECoG Assistant, the first “AI-driven clinician-enabled feature.” It is designed to help epilepsy care using long-term intracranial EEG data.
Built on 124,450 epileptologist-labeled records, the company reported that the tool has “ECoGs of Interest.” It allows physicians to review trends and timing patterns across months through integrated reports and charts, improving efficiency in data review and treatment decisions.
Chief Medical Officer Martha Morrell said the feature “represents an important advancement,” with faster access to insights for more informed care.
CEO Joel Becker said the approval shows how the firm’s data advantage is moving toward “practical tools for clinicians.”
NeuroPace, Inc. (NASDAQ:NPCE) debuted the technology at the ASSFN Annual Meeting on May 30. It has submitted its next-generation patient data platform for FDA review, targeting approval in the second quarter of 2026.
NeuroPace, Inc. (NASDAQ:NPCE) creates, produces, and markets implantable devices to treat epilepsy and neurological illnesses. It offers implantable components such as the RNS neurostimulator and depth and cortical strip leads.
8. Butterfly Network, Inc. (NYSE:BFLY)
Number of Hedge Fund Holders: 26
Butterfly Network, Inc. (NYSE:BFLY) is among the Best Brain-Computer Interface Stocks.
On June 18, Butterfly Network, Inc. (NYSE:BFLY) commented on Midjourney’s launch of a full-body imaging system, outlining its role in the scanner’s underlying hardware and future scaling plans. The company said the current prototype integrates 40 Ultrasound-on-Chip imaging modules per system under an existing co-development agreement. The future versions are expected to use significantly more modules as the platform grows.
CEO Joseph DeVivo called the system “an extraordinary whole-body scanner,” stating it works without radiation or magnetic risk and uses “about half a million sensors” and more than two petaflops of processing power. He added that the device is designed for frequent use, allowing continuous monitoring of physiological changes.
DeVivo said Butterfly Network, Inc. (NYSE:BFLY) supports Midjourney’s effort to expand access to imaging data, calling the roadmap introduced by founder David Holz a potential commercial opportunity. The company also noted its prior agreement outlines up to $74 million in expected payments over five years.
Butterfly Network, Inc. (NYSE:BFLY) develops a medical imaging device that lowers the cost of real-time, three-dimensional imaging and treatment. It develops and markets the iQ Device, a whole-body portable ultrasound scanner, as well as related hosted, web-based applications, application programming interfaces, and platform services to physicians and other licensed health care providers.
7. Bruker Corporation (NASDAQ:BRKR)
Number of Hedge Fund Holders: 34
On June 8, JPMorgan analyst Casey Woodring raised the price target on Bruker Corporation (NASDAQ:BRKR) to $65 from $45. The firm maintained an “Overweight rating” on the share. It updated the company model.
Days earlier, on June 4, Bruker Corporation (NASDAQ:BRKR) reported its growing microbiology and infection diagnostics portfolio at ASM Microbe 2026. The firm detailed advances across microbial identification, sepsis diagnostics, molecular testing, and next-generation sequencing workflows.
The company said improvements to its MALDI Biotyper CA System include FDA-approved updates. It allows spotting of 549 clinically validated microbial species, along with software and workflow upgrades mapped out to improve speed and confidence in clinical labs.
Bruker also introduced new research-use tools. It includes libraries covering 5,325 species and more classifiers planned to strengthen outbreak investigation and surveillance.
The firm added that a rapid antimicrobial susceptibility testing workflow under development could make faster, actionable diagnostics to help earlier clinical decision-making in critically ill patients.
Bruker Corporation (NASDAQ:BRKR) produces diagnostic tests and scientific instruments for customers in the biotechnology, pharmaceutical, applied markets, and life sciences areas.
6. Snap Inc. (NYSE:SNAP)
Number of Hedge Fund Holders: 46
Snap Inc. (NYSE:SNAP) is among the Best Brain-Computer Interface Stocks.
On June 16, Reuters reported that Snap Inc. (NYSE:SNAP) launched its first consumer augmented-reality glasses. These are priced at $2,195, positioning the device as a new computing platform in the artificial intelligence era.
Launched at the Augmented World Expo in California, the report said the “Specs” glasses mark a major hardware push for the firm. The tech company has invested more than $3.5 billion in the specs unit during pressure on its advertising business and calls from an activist investor to spin off or shut it down.
Reuters said the glasses overlay digital content onto real-world views, offering features such as navigation, AI-powered responses, and video capture. Shipping is expected this fall in the US, UK, and France.
CEO Evan Spiegel told Reuters the company built “a totally new type of computer.” He also commented that rising memory chip costs have been “quite impactful” on pricing.
Shares fell 1.6%. Principal analyst at Moor Insights & Strategy, Anshel Sag, told Reuters the price “is still a bit on the high end.”
Snap Inc. (NYSE:SNAP) is a technology company that works on a visual messaging application that was created to help people communicate through short videos and images.
While we acknowledge the potential of SNAP to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SNAP and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Best Brain-Computer Interface Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
